HGP1705

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Erosive Gastroesophageal Reflux DiseaseHealthyHealthy Volunteer

Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-02-15End: 2018-06-15Target: 96Updated: 2018-01-17

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers

CompletedNCT04324905

Hanmi Pharmaceutical Company LimitedHealthy Volunteer

Start: 2020-04-29End: 2020-10-30Updated: 2023-10-25

Phase 3

Efficacy and Safety of HIP1601 Capsule

CompletedNCT04080726

Hanmi Pharmaceutical Company LimitedErosive Gastroesophageal Reflux Disease

Start: 2018-10-25End: 2019-12-03Updated: 2020-11-30

Related Papers

Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated Esomeprazole.

2024-09-161 citations

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.

2023-12-182 citations